MET and non-small cell lung carcinoma: Indeed, it is known that MET amplification promotes proliferation and survival of TKI-treated EGFRm+ NSCLC cells by co-activating MAPK and PI3K/AKT signaling and by inhibiting the proapoptotic proteins BIM and APAF-1 [75,76,77].